bioAffinity Technologies Reports First Quarter 2026 Results and Expansion of CyPath® Lung
bioAffinity Technologies, Inc. reported a 146% year-over-year increase in unit sales of its CyPath® Lung diagnostic test for the first quarter of 2026, highlighting increased physician adoption and clinical use in detecting early-stage lung cancer and other lung diseases.
SAN ANTONIO–(BUSINESS WIRE)—- $BIAF #CyPathLung–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the first quarter ended March 31, 2026. Q1 2026 Highlights CyPath® Lung unit sales increased 146% year-over-year in the first quarter of 2026, reflecting accelerating physician adoption and expanding clinical use of the Company’s no